logo
New pet-ct scan machine and pathology lab for Delhi-NCR

New pet-ct scan machine and pathology lab for Delhi-NCR

Hindustan Times05-05-2025
The Mahajan Imaging and Labs on Sunday inaugurated a state-of-the-art Positron Emission Tomography - Computed Tomograph (PET-CT) scan machine and a pathology lab in Gurugram aimed at enhanced integrated cancer care and pathology services across Delhi NCR.
Officials said the 128 Slice Digital PET-CT-Omni Legend machine is north India's first and is powered by Artificial Intelligence (AI). It has the spatial resolution of 1.4mm, enabling early cancer detection and accurate staging. The machine's features include an advanced digital detector, precision deep learning (DL), AI-based lesion identification, and 60% lower radiation exposure. Further, the system ensures safer and faster scans while delivering high resolution images, said Mahajan Imaging in a statement.
'The launch of our new 128 Slice Digital PET-CT scanner in Gurugram marks a major leap forward in delivering technology-driven cancer diagnostics. With next-generation digital PET-CT scanners, AI-powered imaging, and integrated pathology support, we are empowering clinicians with the precision tools needed for early, accurate detection and better treatment outcomes. Our commitment is to continually raise the bar in oncology care through innovation,' Dr Harsh Mahajan, founder and chairman of Mahajan Imaging, said.
Early detection in cancer remains critical, as at least 70% of cancer cases in India are diagnosed at advanced stages,experts said, largely due to lack of awareness and organised screening programmes, leading to high mortality rates.
According to the Indian Council of Medical Research and data published in The Lancet, the mortality ratio for cancer in India was 64.47% in 2022, indicating that nearly two out of three cancer patients succumbed to the disease after diagnosis.
'As someone who has served both in the medical field and public service, I understand the pivotal role that early and accurate diagnosis plays in the battle against cancer. The introduction of advanced digital PET-CT technology in north India marks more than a technological achievement—it is a beacon of hope for countless families. It exemplifies how we are leveraging innovation with empathy to build a healthier, more equitable future for our citizens,' Union minister of state for science and technology, Jitendra Singh, said. Singh was the chief guest at the launch event.
The minister added, 'The central government recognises the cancer burden and has taken measures to ensure access to cancer care by setting up 200 day care cancer centres in district hospitals this year besides full customs duty exemption on 36 diseases which are rare and chronic.'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Rs 1 lakh crore fund to boost private sector R&D: Jitendra Singh
Rs 1 lakh crore fund to boost private sector R&D: Jitendra Singh

Time of India

time6 hours ago

  • Time of India

Rs 1 lakh crore fund to boost private sector R&D: Jitendra Singh

Science and Technology Minister Jitendra Singh on Friday said that a fund of Rs 1 lakh crore will to boost the private sector to drive India's sovereign technology ambitions. Singh made these remarks while addressing the ASSOCHAM Conference on "Sovereign Tech for India's Digital Transformation " here. Explore courses from Top Institutes in Please select course: Select a Course Category Degree CXO Data Science Product Management Operations Management Project Management Artificial Intelligence Technology Management Healthcare Design Thinking Digital Marketing MBA Data Science Others Leadership others Cybersecurity PGDM Finance Public Policy healthcare Data Analytics MCA Skills you'll gain: Data-Driven Decision-Making Strategic Leadership and Transformation Global Business Acumen Comprehensive Business Expertise Duration: 2 Years University of Western Australia UWA Global MBA Starts on Jun 28, 2024 Get Details He said the government has launched the ambitious Research, Development, and Innovation (RDI) Scheme to transform private sector R&D, particularly in sunrise and strategic sectors. Singh said the scheme will provide long-term, low-interest loans and risk capital to support deep-tech, critical technologies , and transformative projects. A dedicated 'Deep-Tech Fund of Funds' will also be established to scale up private investment in innovation. Live Events The scheme will be anchored by the Anusandhan National Research Foundation (ANRF) and implemented by the Department of Science and Technology (DST), Singh said. "We appeal to the industry to come forward and harness the full spectrum of opportunities opened up by the Government. India's technological footprint is expanding, and the world is watching," Singh said. PTI

Rs 1 lakh crore fund to boost private sector R&D: Jitendra Singh
Rs 1 lakh crore fund to boost private sector R&D: Jitendra Singh

News18

time7 hours ago

  • News18

Rs 1 lakh crore fund to boost private sector R&D: Jitendra Singh

New Delhi, Aug 1 (PTI) Science and Technology Minister Jitendra Singh on Friday said that a fund of Rs 1 lakh crore will to boost the private sector to drive India's sovereign technology ambitions. Singh made these remarks while addressing the ASSOCHAM Conference on 'Sovereign Tech for India's Digital Transformation" here. He said the government has launched the ambitious Research, Development, and Innovation (RDI) Scheme to transform private sector R&D, particularly in sunrise and strategic sectors. Singh said the scheme will provide long-term, low-interest loans and risk capital to support deep-tech, critical technologies, and transformative projects. A dedicated 'Deep-Tech Fund of Funds' will also be established to scale up private investment in innovation. 'We appeal to the industry to come forward and harness the full spectrum of opportunities opened up by the Government. India's technological footprint is expanding, and the world is watching," Singh said. PTI SKU SKU SKY SKY view comments First Published: August 01, 2025, 21:00 IST Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.

70 pc enrolment of participants for Phase III clinical trial of dengue vaccine completed: Centre
70 pc enrolment of participants for Phase III clinical trial of dengue vaccine completed: Centre

The Print

time12 hours ago

  • The Print

70 pc enrolment of participants for Phase III clinical trial of dengue vaccine completed: Centre

'The trial involves over 10,000 participants, out of which more than 70 per cent enrolment has been completed. The trial has been implemented in 20 sites across India,' he said. The Indian Council of Medical Research (ICMR) has undertaken a clinical trial titled phase III, multicentre, randomised, double-blind, placebo controlled study to evaluate the efficacy, immunogenicity and safety of the single-dose Dengue Tetravalent vaccine, live attenuated (Recombinant, Lyophilised) – 'DengiAll', Jadhav said in a written reply. New Delhi, Aug 1 (PTI) Seventy per cent enrolment of participants for the Phase III clinical trial of the indigenous one-shot dengue vaccine, DengiAll, has been completed, Minister of State for Health, Prataprao Jadhav, told Lok Sabha on Friday. The sites are JSS Medical College and Hospital, Mysuru (Karnataka), Bangalore Medical College and Research Institute, and All India Institute of Medical Sciences, Bibinagar (Telangana). The approximate budget for the trial is Rs 1.3 to 1.5 crore per site, Jadhav said. According to ICMR, there is no specific antiviral treatment or licensed vaccines for dengue and the treatment is supportive in nature, Jadhav said. A total of 5,73,563 laboratory confirmed dengue cases were reported through the Integrated Health Information Platform (IHIP) in 2024, according to information shared by the National Centre for Disease Control (NCDC) , . According to ICMR, all four serotypes of the dengue virus (DENV-1, DENV-2, DENV-3, and DENV -4) are known to circulate and co-circulate in India. Multiple serotypes can be present in the same geographical region and can even infect the same individual at the same time. Hence, participants have been enrolled in the ICMR vaccine trial from different zones where these four serotypes circulate in order to test the efficacy of the vaccine against all four serotypes, Jadhav said. The minister also said that the Union Health Ministry, Director General of Health Services, and National Centre for Vector Borne Disease Control (NCVBDC) regularly monitor the situation of dengue outbreaks across the country for assessing the disease situation, preparedness, technical guidance and to sensitise and forewarn the states. Under the National Health Mission, adequate budgetary support is provided to states and Union territories for dengue control activities such as epidemic preparedness, monitoring, case management, vector control (provision of domestic breeding checkers, ASHA involvement, insecticide, fogging machines), training, intersectoral convergence, awareness activities, etc. For surveillance and free of cost diagnosis of dengue, Sentinel Surveillance Hospitals with laboratory facility and Apex Referral laboratories with advance diagnostic facilities have been identified across the country, Jadhav said. The government of India has developed national guidelines on dengue treatment/management, in consultation with experts, which have been shared with all the states and UTs for implementation. The guidelines emphasise the preparedness of hospitals for case treatment/management. In addition, advisories have been issued from time to time to states/UTs for prevention and control of dengue, including case management, the minister said. PTI PLB ARI This report is auto-generated from PTI news service. ThePrint holds no responsibility for its content.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store